retatrutide clinical trial results 2024 2025 retatrutide weight loss study Where to Get: Can You Buy Online in 2026? Retatrutide Results: 24% Weight Loss

Unlike traditional weight-loss medications that target single pathways, this innovative

Obesity affects 42% of adults in the United States and is strongly associated with major cardiovascular disease risk factors, including high blood pressure, abnormal cholesterol levels, and insulin resistance, making effective obesity treatment a critical public health priority.

Extreme energy fast*

Metabolaid 6.9% GLP-1

Recent evidence from the STEP-HFpEF and STEP-HFpEF-DM trials provides the first robust data supporting the efficacy of GLP-1 RAs, specifically semaglutide, in improving the quality of life in obese patients with HFpEF

Leading Players in the GLP-1 Market Novo Nordisk 38.72% Ozempic Wegovy Rybelsus Eli Lilly 28.41% Mounjaro Zepbound Sanofi 8.76% 4 AstraZeneca 6.62% 5 GSK 4.95% 6 Regeneron 3.27% 7 Pfizer 2.61% 8 Amgen 1.98% 9 Sun Pharma 1.52% Boehringer Ingelheim 1.24% Together, Novo Nordisk and Eli Lilly account for more than 67% of the market, highlighting the intense competition between the two companies that currently lead the obesity and diabetes treatment revolution